Navigation Links
Sorafenib Slows Growth of Some Leukemias
Date:2/1/2008

Drug shows potential for patients with specific gene mutations, researchers find

FRIDAY, Feb. 1 (HealthDay News) -- The drug sorafenib shows promise in the treatment of people with acute myeloid leukemia who have specific gene mutations, say U.S. researchers.

Previous research has shown that sorafenib -- currently used to treat kidney and liver cancer -- is effective against acute myeloid leukemia cells that have internal tandem duplication (ITD) mutations of the Fms-like tyrosine kinase 3 (FLT3) gene, according to background information in the study.

Researchers at the University of Texas M.D. Anderson Cancer Center in Houston looked at sorafenib's effect on leukemia cells that express either the common or mutant copies of FLT3. They also gave the drug to mice with leukemia cells with known FLT3 mutations and to leukemia patients with and without the FLT3 mutation.

Sorafenib slowed growth and induced cell death in the FLT3 mutant leukemia cells and increased survival of the mice with FLT3 mutant leukemia. The drug also reduced the percentage of leukemia cells in the blood and marrow of leukemia patients with the FLT3 mutation but not in leukemia patients without the mutation.

"Our findings imply that sorafenib is a potent anti-leukemic agent in patients with FLT3-ITD mutant [acute myeloid leukemia], a form of [the disease] that responds poorly to traditional chemotherapy," the study authors concluded.

The findings were published in the Jan. 29 issue of the Journal of the National Cancer Institute.

More information

The American Cancer Society has more about acute myeloid leukemia.



-- Robert Preidt



SOURCE:Journal of the National Cancer In
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Health Insurance Premium Growth Slows for Fourth Straight Year
2. Philanthropic Giving for Health Care Slows in 2006 in both U.S. and Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
3. Drug slows prostate tumor growth by keeping vitamin A active
4. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
5. High pollution linked to poor lung function growth in children in Mexico City
6. Researchers develop long-lasting growth hormone
7. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
8. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
9. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
10. AWT Management Announce Aggressive Growth and Acquisition Strategy
11. Cynosure to Present at the Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sorafenib Slows Growth of Some Leukemias
(Date:7/9/2014)... stromal support cells and immune cells and the ... the development of diseases could open new therapeutic ... the conclusion of a review article by scientists from ... Nature . , Prof. Peter Carmeliet: "Consider the review ... cancer cells has been examined in minute detail for ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
(Date:7/9/2014)... microbiologists from the Keck School of Medicine of ... that mice lacking a specific component of the ... potentially fatal complication of infection. The discovery suggests ... reduce inflammation in human autoimmune and hyper-inflammatory diseases ... , The study was published online on June ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... U.S. Department of Energy,s (DOE) Brookhaven National Laboratory have ... design of a "medical synchrotron" capable of delivering precision ... damage to surrounding healthy tissue. The new device would ... systems, potentially increasing the availability and benefits of this ...
... There is a new,Internet service available that changes the ... stay informed, it allows,long-term care providers to give them regular ... text message without families having,to call, no matter where they ... to do and too little time. It,s a common problem ...
... and digital radiography highlighted at RSNA 2008 , ... Siemens Healthcare ( ... from fluoroscopy and digital radiography to interventional radiology, at ... Radiological Society of North America (RSNA) from November 30 ...
... Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today that ... Conference on Wednesday, December 3, 2008 at 4:30p.m. ET at ... , The live and archived ... of Events" in the Idenix Investor Center at www.idenix.com ...
... Inc.,(Nasdaq: CEPH ) and ImmuPharma PLC (LSE: ... have signed an Option Agreement,providing Cephalon with an option ... Lupuzor(TM) for the treatment of Systemic Lupus,Erythematosus. ImmuPharma ... in patients in Europe and Latin America. , ...
... 25 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... monoclonal antibodies for the treatment of serious ... U.S. Patent and Trademark,Office has issued U.S. ... covering anti-viral applications of antibodies that directly ...
Cached Medicine News:Health News:Physicists receive patent for improved cancer therapy device 2Health News:Physicists receive patent for improved cancer therapy device 3Health News:New Internet Service Delivers Relief to Families of Those in Long-Term Care 2Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 2Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 3Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 4Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 5Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 6Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 2Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 3Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 4Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 3Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 4
(Date:1/15/2014)... DUBLIN , Jan. 15, 2014  Research and Markets ... "Dental Consumables Market - Global Industry Analysis, Size, ... report to their offering. (Logo: ... products which are used on patients in order to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... DIEGO, Aug. 12, 2011 / PRNewswire/ -- Halozyme ... company developing and commercializing products targeting the extracellular ... at the Wedbush 2011 Life Sciences Conference in New ... at 9:10 a.m. EDT (6:10 a.m. PDT). To listen ...
... WOODLANDS, Texas, Aug. 11, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... , Lexicon,s president and chief executive officer, will present ... on Tuesday, August 16, 2011 at 1:15 p.m. Eastern ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 2Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: